Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eravacycline pulmonary bronchial fluid pharmacokinetics in adults with HAP/VAP
ChiCTR2400087137Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of eravacycline in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (4 arms), sponsored by Huashan Hospital. Primary endpoints: Drug concentration in plasma and Drug concentration in pulmonary bronchial fluid. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
eravacycline
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on ChiCTR2400087137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087137.